9.81

0.30% -0.03

4 D Molecular Therapeutics Inc (FDMT)

Overview News Price History Option Chain Financials Discussions Forecast

4 D Molecular Therapeutics Inc stock is traded at $9.81, with a volume of 900.75K. It is down -0.30% in the last 24 hours and up +10.60% over the past month. 4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

Previous Close:

$9.84

Open:

$9.82

24h Volume:

900.75K

Relative Volume:

1.17

Market Cap:

$500.82M

Revenue:

$85.21M

Net Income/Loss:

$-140.11M

P/E Ratio:

-3.9012

EPS:

-2.5146

Net Cash Flow:

$-109.62M

1W Performance:

+3.48%

1M Performance:

+10.60%

6M Performance:

+10.22%

1Y Performance:

+278.76%

1-Day Range:

$9.49

$9.94

1-Week Range:

$9.49

$10.88

52-Week Range:

$2.465

$12.34

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name

4 D Molecular Therapeutics Inc

Sector

Healthcare (1105)

Industry

Biotechnology (623)

Phone

(510) 505-2680

Address

5858 HORTON STREET #455, EMERYVILLE

Employee

196

Twitter

Next Earnings Date

2026-03-20

Latest SEC Filings

FDMT's Discussions on Twitter

Compare FDMT vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FDMT 4 D Molecular Therapeutics Inc	9.81	500.82M	85.21M	-140.11M	-109.62M	-2.5146
VRTX Vertex Pharmaceuticals Inc	436.27	110.97B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	748.87	79.17B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	799.65	49.73B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	322.11	42.98B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	309.66	34.37B	5.36B	287.73M	924.18M	2.5229

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Resumed	Barclays	Overweight
Nov-07-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jan-13-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
Nov-21-24	Initiated	Morgan Stanley	Underweight
Sep-23-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-15-24	Initiated	Barclays	Overweight
Feb-07-24	Resumed	Goldman	Buy
Oct-26-23	Initiated	RBC Capital Mkts	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Chardan Capital Markets	Buy
Jan-30-23	Initiated	BMO Capital Markets	Outperform
Nov-18-22	Initiated	H.C. Wainwright	Buy
Nov-15-22	Upgrade	Goldman	Neutral → Buy
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-22-22	Initiated	Jefferies	Buy
Jan-04-22	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	BofA Securities	Buy
Jan-05-21	Initiated	Evercore ISI	Outperform
Jan-05-21	Initiated	Goldman	Neutral

View All

4 D Molecular Therapeutics Inc Stock (FDMT) Latest News

Apr 11, 2026

Layoff Watch: What is the Moat Score of 4D Molecular Therapeutics Inc2026 Short Interest & AI Based Buy and Sell Signals - baoquankhu1.vn

Apr 11, 2026

Apr 07, 2026

Janus Henderson (NASDAQ: FDMT) holds 5.25M shares, 10.3% stake in 4D Molecular - Stock Titan

Apr 07, 2026

Apr 06, 2026

Investment Analysts’ Recent Ratings Changes for 4D Molecular Therapeutics (FDMT) - Defense World

Apr 06, 2026

Apr 03, 2026

JPMorgan Chase & Co. Has $4.46 Million Stock Holdings in 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat

Apr 03, 2026

Mar 31, 2026